Cytokinetics, Inc. Stock Nasdaq
Stocks
US23282W1009
Biotechnology & Medical Research
|
End-of-day quote
Other stock markets
|
||
| - USD | - |
|
| Market Cap | 10.47B 9.07B 8.45B 7.76B 14.68B 999B 14.87B 99.5B 39.03B 498B 39.32B 38.46B 1,652B | P/E 2026 * |
-12.1x | P/E 2027 * | -16.5x |
|---|---|---|---|---|---|
| Enterprise Value | 9.89B 8.56B 7.98B 7.33B 13.85B 943B 14.04B 93.93B 36.85B 470B 37.12B 36.31B 1,560B | EV / Sales 2026 * |
87.6x | EV / Sales 2027 * | 25.1x |
| Free-Float |
98.24% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Cytokinetics, Inc.
| Manager | Title | Age | Since |
|---|---|---|---|
Robert Blum
CEO | Chief Executive Officer | 62 | 2006-12-31 |
Sung Lee
DFI | Director of Finance/CFO | 55 | 2024-05-07 |
Fady Malik
CTO | Chief Tech/Sci/R&D Officer | 61 | 2015-11-12 |
| Director | Title | Age | Since |
|---|---|---|---|
Robert Blum
BRD | Director/Board Member | 62 | 2006-12-31 |
John Henderson
CHM | Chairman | 81 | 2022-04-07 |
Wendell Wierenga
BRD | Director/Board Member | 78 | 2011-02-08 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +2.35% | +2.74% | +38.10% | +71.29% | 56.54B | |
| -0.21% | -7.38% | +27.52% | +63.59% | 53.6B | |
| -2.44% | +1.40% | -15.61% | -13.72% | 22.91B | |
| -2.85% | -7.78% | -9.28% | +352.92% | 21.37B | |
| +2.49% | -0.92% | +23.57% | -13.14% | 20.27B | |
| +0.79% | -1.06% | +33.99% | -31.95% | 17.56B | |
| +0.58% | -5.88% | +19.40% | +527.50% | 14.75B | |
| +3.41% | -6.61% | +162.81% | +278.22% | 13.53B | |
| -5.25% | -4.23% | +42.32% | +160.72% | 13.33B | |
| Average | -0.13% | -3.79% | +35.87% | +155.05% | 25.98B | |
| Weighted average by Cap. | +0.23% | -2.96% | +30.79% | +117.70% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 113M 97.77M 91.11M 83.67M 158M 10.76B 160M 1.07B 421M 5.36B 424M 415M 17.81B | 393M 341M 318M 292M 551M 37.52B 559M 3.74B 1.47B 18.69B 1.48B 1.44B 62.06B |
| Net income | -796M -690M -643M -590M -1.12B -75.93B -1.13B -7.57B -2.97B -37.84B -2.99B -2.92B -126B | -655M -567M -528M -485M -918M -62.44B -930M -6.22B -2.44B -31.11B -2.46B -2.4B -103B |
| Net Debt | -586M -508M -473M -435M -822M -55.92B -832M -5.57B -2.19B -27.86B -2.2B -2.15B -92.5B | -606M -525M -489M -449M -849M -57.76B -860M -5.75B -2.26B -28.78B -2.27B -2.22B -95.55B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Select your edition
All financial news and data tailored to specific country editions
